Lurbinectedin plus atezolizumab maintenance in extensive-stage small-cell lung cancer: breaking the four-decade stalemate or exposing the limits of incremental progress?

For more than forty years, extensive-stage small-cell lung cancer (ES-SCLC) has resisted meaningful therapeutic progress. Despite an initially exquisite sensitivity to platinum-etoposide chemotherapy, most patients relapse within months, and median overall survival (OS) has remained stubbornly anchored around twelve to thirteen months (1,2). The advent of immune checkpoint inhibitors offered a tantalizing glimpse of durable benefit, but the absolute gains—a matter of a few months in landmark trials such as IMpower133 (atezolizumab in combination with carboplatin + etoposide in patients with untreated extensive-stage small cell lung cancer) and CASPIAN (durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer)—left the community yearning for transformative breakthroughs (3,4). Against this backdrop, the IMforte (lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer) trial emerges as both a milestone and a provocation: it is the first phase 3 study to demonstrate that escalating treatment intensity during the maintenance phase—specifically, by adding the DNA-binding cytotoxic agent lurbinectedin to atezolizumab—yields statistically significant and clinically meaningful improvements in progression-free survival (PFS) and OS when compared with atezolizumab maintenance alone (5). Yet, as we unpack the trial’s design, efficacy signals, toxicity profile, and mechanistic underpinnings, a more nuanced picture emerges—one that forces us to confront the tension between incremental progress and the bold, biomarker-driven strategies required to genuinely alter the natural history of this ruthless malignancy.

The IMforte trial enrolled 660 patients into an induction phase consisting of four cycles of atezolizumab, carboplatin, and etoposide—a regimen that has become the de facto standard following the IMpower133 results (3). Patients who achieved at least stable disease and maintained an ECOG performance status of 0 or 1 were then randomized one-to-one to receive either lurbinectedin (3.2 mg/m² every three weeks) plus atezolizumab (1,200 mg every three weeks) or atezolizumab monotherapy. Of the 660 who started induction, 483 (73%) reached the randomization milestone, whereas 177 patients (27%) did not proceed to maintenance due to early progression (n=56), death (n=36), adverse events (n=21), or deteriorating performance status. Within the randomized cohort, 88% had documented objective responses and 11% had stable disease at the onset of maintenance, underscoring a highly curated, enriched population likely to derive benefit from further therapy. Notably, patients with untreated or symptomatic central nervous system (CNS) metastases were excluded—a pragmatic but consequential decision given that CNS involvement is present in approximately 10–15% of newly diagnosed ES-SCLC cases and ultimately develops in 40–50% of patients over the disease course (6). Lurbinectedin exhibits limited CNS penetration, and the exclusion of this high-risk subgroup raises immediate questions about the generalizability of the trial’s findings to the broader ES-SCLC population.

The primary efficacy endpoints—PFS assessed by independent review and OS—were measured from the date of randomization into maintenance, a time-zero definition that merits careful interpretation. From that maintenance baseline, median PFS more than doubled, rising from 2.1 months in the atezolizumab-alone arm to 5.4 months in the combination arm [hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.43–0.67; P<0.001]. Median OS also favored the experimental regimen, increasing from 10.6 months to 13.2 months [HR 0.73, 95% CI 0.57–0.95; P=0.02], translating to an absolute OS gain of approximately 2.6 months within the maintenance window. When one accounts for the roughly three-month induction period preceding maintenance, the total median OS from first treatment exposure is estimated at approximately 16–17 months in the lurbinectedin-atezolizumab cohort versus 13–14 months in the control group—a perspective that contextualizes the benefit relative to historical benchmarks. These are not trivial gains; in a disease where median survivals have historically plateaued, an additional few months can represent meaningful time for patients and their families. Nevertheless, the magnitude of improvement remains modest when weighed against the disease’s aggressive biology, the substantial attrition before maintenance, and the toxicity incurred.

Toxicity, indeed, is a central consideration. Grade 3–4 adverse events (AEs) occurred in 38% of patients receiving lurbinectedin plus atezolizumab, compared with 22% in the atezolizumab monotherapy arm. The most common severe toxicities in the combination group were hematologic: anemia (8% versus 0%), neutropenia (7% versus 0%), and thrombocytopenia (7% versus <1%). Serious AEs were reported in 31% of the combination arm versus 17% of the control, and grade 5 (fatal) events occurred in 5% versus 3%, with two treatment-related deaths attributed to sepsis and febrile neutropenia in the experimental cohort (5). Despite prophylactic use of granulocyte colony-stimulating factors, the cumulative myelosuppressive burden was considerable, and fewer patients in the combination arm went on to receive subsequent chemotherapy (37% versus 49%), suggesting either depletion of bone marrow reserve or a shift in treatment goals as the disease advanced. These safety signals underscore the need for vigilant patient selection, careful monitoring of performance status and hematologic parameters, and transparent shared decision-making that weighs the prospect of prolonged disease control against the risk of meaningful toxicity.

A particularly compelling dimension of IMforte lies in its mechanistic rationale, which centers on the concept of immunogenic cell death (ICD) and the role of damage-associated molecular patterns (DAMPs) (Figure 1). Lurbinectedin is a synthetic alkaloid that binds selectively to the minor groove of DNA, inducing structural distortion, strand breaks, and transcriptional inhibition that culminate in tumor cell apoptosis (7,8). Critically, lurbinectedin-induced cell death is not immunologically silent; rather, it triggers the release or surface exposure of DAMPs—including calreticulin (CALR), high-mobility group box 1 (HMGB1), and annexin A1 (ANXA1)—that serve as “danger signals” to the innate immune system (9,10). In parallel, DNA damage activates the cytosolic DNA-sensing cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, leading to the production of type I interferons and pro-inflammatory chemokines that recruit and activate antigen-presenting cells (11,12). This cascade enhances dendritic cell maturation, facilitates cross-presentation of tumor antigens, and primes CD8⁺ T cell responses, thereby converting an immunologically “cold” tumor microenvironment into a more inflamed, immune-permissive state. Recent preclinical work has demonstrated that STING is essential for lurbinectedin’s immunomodulatory effects: pharmacologic or genetic ablation of STING abolishes the induction of ICD markers, the upregulation of major histocompatibility complex molecules, and the infiltration of CD8+ T cells following lurbinectedin exposure (12). Furthermore, translational studies in patient-derived SCLC samples have documented upregulation of 4-1BB (CD137), a costimulatory molecule on activated T cells, and increased expression of PD-L1 on tumor cells and infiltrating immune cells after lurbinectedin treatment (12,13). These observations provide a cogent mechanistic framework for combining lurbinectedin with anti-PD-L1 therapy: by inducing ICD and activating the STING pathway, lurbinectedin may sensitize tumors to immune checkpoint blockade, synergistically enhancing anti-tumor immunity.

Figure 1 Lurbinectedin-mediated immunogenic cell death and cGAS-STING pathway activation in SCLC. Lurbinectedin binds the DNA minor groove, inducing DNA damage, strand breaks, and transcriptional inhibition by RNA POL II (RNA polymerase II) that trigger apoptosis and the release of damage-associated molecular patterns (DAMPs), including CALR/CRT (calreticulin), HMGB1 (high-mobility group box 1), and ANXA1 (annexin A1). Cytosolic DNA fragments activate the cGAS-STING pathway through pTBK1 (phosphorylated TANK-binding kinase 1) and pIRF3 (phosphorylated interferon regulatory factor 3), leading to pSTING (phosphorylated STING) activation, type I interferons IFNα/β (interferons alpha and beta) production, ATP (adenosine triphosphate) release, dendritic cell (DC) maturation, and CD8⁺ T cell priming. This immunogenic cell death (ICD) process sensitizes tumors to PD-L1 blockade by converting immunologically “cold” microenvironments into inflamed, immune-permissive states. cGAS, cyclic GMP-AMP synthase; SCLC, small-cell lung cancer; STING, stimulator of interferon genes.

However, the mechanistic elegance should not obscure several critical uncertainties. First, the extent to which lurbinectedin-induced ICD translates into durable immunologic memory in the clinic remains unclear, particularly given the immunosuppressive milieu often present in ES-SCLC. Chronic inflammation can paradoxically promote immune exhaustion and the recruitment of regulatory T cells or myeloid-derived suppressor cells, potentially limiting long-term efficacy. Second, the molecular heterogeneity of SCLC—captured by transcriptomic subtypes such as SCLC-A (ASCL1-driven, neuroendocrine-high), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven, tuft-cell-like), and SCLC-I (inflamed, immune-enriched)—suggests that not all tumors will respond equivalently to ICD-inducing therapies (14,15). Tumors with pre-existing immune infiltrates (SCLC-I) may be primed for checkpoint inhibition and could derive maximal benefit from lurbinectedin’s immunostimulatory effects, whereas neuroendocrine-high, immune-cold subtypes (SCLC-A) may require additional interventions to overcome intrinsic resistance. Third, the CNS sanctuary remains a persistent challenge: even if systemic disease is controlled, the limited CNS penetration of both lurbinectedin and large-molecule immunotherapies leaves a reservoir of disease poised to relapse. The exclusion of patients with CNS metastases from IMforte thus represents both a pragmatic trial design choice and a missed opportunity to address one of the most clinically consequential dimensions of ES-SCLC biology.

These considerations invite reflection on whether the maintenance paradigm exemplified by IMforte truly represents a ceiling or a floor. The modest absolute OS gains and the substantial toxicity profile argue that we are still operating within an incremental framework rather than achieving the transformative breakthroughs that patients desperately need. Emerging data on DLL3-targeted therapies offer a tantalizing counterpoint: tarlatamab, a bispecific T cell engager (BiTE) that redirects T cells to DLL3-expressing tumor cells, has demonstrated remarkable activity in heavily pretreated SCLC, with objective response rates of approximately 40%, a median overall survival of 15.2 months, and a six-month OS rate exceeding 73% in the DeLLphi-301 and DeLLphi-304 trials (16,17). From a practical standpoint, lurbinectedin-based maintenance can be administered in the outpatient setting with primarily hematologic toxicity requiring vigilant monitoring of blood counts, whereas tarlatamab necessitates initial inpatient or step-up dosing protocols due to the risk of cytokine release syndrome (CRS), which may limit its accessibility in community practice settings. This addition provides clinicians with actionable information for treatment selection. DLL3 is highly expressed in the majority of SCLC tumors and represents a lineage-specific target with limited normal tissue expression, offering a potentially safer and more effective alternative or complement to cytotoxic maintenance strategies. Similarly, antibody-drug conjugates (ADCs) such as ifinatamab deruxtecan—targeting B7-H3 with a topoisomerase I inhibitor payload—are showing early promise and may reshape the therapeutic landscape in the near term (18). The juxtaposition of these novel, targeted approaches with the incremental gains seen in IMforte underscores the urgency of moving beyond one-size-fits-all maintenance toward precision, biomarker-driven strategies.

Several key questions remain unanswered and should guide future investigation. First, what is the optimal timing for immune priming in ES-SCLC—should lurbinectedin (or other ICD-inducing agents) be integrated earlier, during the induction phase, to maximize the duration of immune activation and minimize the risk of early relapse? Front-loading immune priming might allow for more durable systemic control and spare patients the cumulative toxicity of prolonged maintenance. Second, can we prospectively identify which patients are most likely to benefit from lurbinectedin-based maintenance? Candidate biomarkers include baseline STING pathway activity, circulating tumor DNA (ctDNA) dynamics, transcriptomic subtype classification, and immune gene signatures; integrating these tools into adaptive, biomarker-stratified trial designs would enable real-time decision-making and more efficient allocation of therapeutic resources. Third, how do we address the CNS sanctuary problem? Strategies might include CNS-penetrant small-molecule inhibitors, intrathecal or intraventricular delivery of novel agents, focused radiotherapy, or combinations that disrupt the blood-brain barrier and enhance drug delivery. Fourth, how do we balance efficacy and quality of life? Patient-reported outcomes, including measures of symptom burden, functional status, and overall well-being, should be co-primary endpoints in future trials, ensuring that survival gains translate into meaningful improvements in lived experience.

It is also crucial to situate IMforte within the broader therapeutic landscape and to acknowledge the context of prior maintenance trials. CheckMate 451, which evaluated nivolumab with or without ipilimumab as maintenance therapy after platinum-etoposide induction, failed to meet its primary OS endpoint, highlighting the challenges of late-stage immune intervention in a disease characterized by rapid tumor doubling times and early immune escape (19). The MERU (rovalpituzumab tesirine as a maintenance therapy) trial, exploring rovalpituzumab tesirine (an anti-DLL3 ADC) in maintenance, was discontinued due to lack of efficacy and concerning toxicity, underscoring the difficulty of targeting this antigen with first-generation ADC platforms (20). Against these disappointments, IMforte’s positive signal is notable—but it is tempered by the recognition that the benefit accrues to a highly selected, enriched population and comes at the cost of increased toxicity and potential compromise of subsequent therapy options.

From a practical standpoint, clinicians must now integrate IMforte’s findings into daily practice while awaiting further data and novel alternatives. For patients with ES-SCLC who respond to induction chemoimmunotherapy, have preserved performance status, adequate marrow reserve, and no CNS involvement, lurbinectedin plus atezolizumab represents a rational and evidence-based maintenance strategy. However, shared decision-making is paramount: patients should be informed of the absolute magnitude of benefit, the risk of hematologic toxicity, the potential impact on subsequent treatment options, and the emerging alternatives such as DLL3-targeted therapies that may soon become available. For patients with CNS metastases, impaired performance status, or marginal marrow function, alternative approaches—including close surveillance, participation in biomarker-driven trials, or consideration of novel targeted agents—should be prioritized.

Looking forward, the field must embrace adaptive trial designs that allow for real-time integration of biomarkers and patient-level heterogeneity. Basket and umbrella trials that stratify patients by molecular subtype, immune signature, or ctDNA burden can accelerate the identification of predictive biomarkers and enable more personalized treatment algorithms. Combination strategies that pair lurbinectedin with DLL3-targeted therapies, PARP inhibitors, or next-generation immunotherapies warrant rigorous investigation, as do sequencing studies that define the optimal order and timing of interventions. Importantly, correlative science should be embedded in every trial, with mandatory tumor biopsies, serial blood sampling for ctDNA and immune profiling, and comprehensive quality-of-life assessments to ensure that we are capturing the full spectrum of therapeutic impact.

In conclusion, IMforte represents a landmark achievement: it is the first phase 3 trial to demonstrate that intensifying maintenance therapy in ES-SCLC can yield statistically significant and clinically meaningful improvements in PFS and OS. The mechanistic rationale—anchored in lurbinectedin’s capacity to induce ICD, release DAMPs, and activate the cGAS-STING pathway—provides a compelling biological foundation for combining cytotoxic agents with immune checkpoint inhibitors. However, it is critical to recognize that these survival improvements are measured from the maintenance randomization point in a highly selected population of responders, not from the initiation of first-line therapy. The trial limitations—including 27% attrition before maintenance, exclusion of CNS metastases, modest absolute survival gains when contextualized from diagnosis, and significant toxicity—remind us that we are still navigating incremental progress rather than achieving transformative breakthroughs (Table 1). The emergence of DLL3-targeted therapies and other novel agents offers the promise of truly disruptive innovation, and the challenge before us is to move beyond one-size-fits-all maintenance toward precision, biomarker-driven strategies that genuinely alter the trajectory of ES-SCLC. IMforte should thus be celebrated as a floor, not a ceiling—a foundation upon which to build the next generation of adaptive, patient-centered trials that will, we hope, finally break the four-decade stalemate and deliver the transformative outcomes that our patients so urgently deserve.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Shanghai Chest. The article has undergone external peer review.

Peer Review File: Available at https://shc.amegroups.com/article/view/10.21037/shc-2026-1-0002/prf

Funding: None.

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://shc.amegroups.com/article/view/10.21037/shc-2026-1-0002/coif). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 2021;7:3. [Crossref] [PubMed]
2. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 2017;17:725-37. [Crossref] [PubMed]
3. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9. [Crossref] [PubMed]
4. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39. [Crossref] [PubMed]
5. Paz-Ares L, Borghaei H, Liu SV, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet 2025;405:2129-43. [Crossref] [PubMed]
6. Seute T, Leffers P, ten Velde GP, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 2008;112:1827-34. [Crossref] [PubMed]
7. Leal JF, Martínez-Díez M, García-Hernández V, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 2010;161:1099-110. [Crossref] [PubMed]
8. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21:645-54. [Crossref] [PubMed]
9. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72. [Crossref] [PubMed]
10. Garg AD, Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev 2017;280:126-48. [Crossref] [PubMed]
11. Vanpouille-Box C, Hoffmann JA, Galluzzi L. Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat Rev Drug Discov 2019;18:845-67. [Crossref] [PubMed]
12. Chakraborty S, Sen U, Ventura K, et al. Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Cell Rep Med 2024;5:101852. [Crossref] [PubMed]
13. Calles A, Calvo E, Santamaría Nuñez G, et al. Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer. Mol Cancer Ther 2025;24:828-39. [Crossref] [PubMed]
14. Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289-97. [Crossref] [PubMed]
15. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39:346-360.e7. [Crossref] [PubMed]
16. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med 2023;389:2063-75. [Crossref] [PubMed]
17. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 2025;393.
18. Rudin CM, Johnson ML, Paz-Ares L, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol 2026;44:261-73. [Crossref] [PubMed]
19. Owonikoko TK, Park K, Govindan R, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol 2021;39:1349-59. [Crossref] [PubMed]
20. Johnson ML, Zvirbule Z, Laktionov K, et al. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J Thorac Oncol 2021;16:1570-81. [Crossref] [PubMed]